• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

PCI Biotech and eTheRNA immunotherapies initiate research collaboration

Exploring synergies between PCI and TriMix technologies to further enhance the effect of novel oncologic therapies

Oslo (Norway) and Niel (Belgium), 8 December 2016 — PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and eTheRNA immunotherapies NV, a VUB spin-off company backed by strong life science investors to continue the development of mRNA-based immunotherapies, today announced that they are initiating a preclinical research collaboration.

eTheRNA to appoint Dr. Russell G. Greig as Chairman of the Board

Appointment of highly reputed chairman marks eTheRNA’s ambitions in the cancer immunotherapy area

Dr. Russell G. Greig - Chairman of the Board Niel (Belgium), 14 September 2016 — eTheRNA immunotherapies NV, the VUB spin-off that recently secured a EUR 24 million investment to continue the development of mRNA-based immunotherapies, has appointed Dr. Russell G. Greig as Chairman of the Board. Dr. Greig’s mandate as chairman has become effective as of September 13, 2016.

eTheRNA strengthens management team with the appointment of Alain Deloof as head of the mRNA production lab

eTheRNA is on track to move the mRNA production unit from Jette to Niel in 2017 and to triple its capacity

Alain Deloof - Head of the mRNA production lab Brussels (Belgium), 4 August 2016 — eTheRNA immunotherapies NV, the VUB spin-off that recently secured a EUR 24 million investment to continue the development of mRNA-based immunotherapies, has strengthened its management team with the appointment of Alain Deloof (foto) as Production Lead , effective August 1, 2016.

Tijd 50 - De Belgen die uw leven zullen redden

Welke ondernemers, dokters en wetenschappers maken het verschil in onze gezondheidszorg?

De Tijd ging op zoek naar de vijftig ondernemers, onderzoekers, dokters en mecenassen die het verschil maken in de gezondheidszorg. Of ze nu aan het hoofd staan van een onderzoeksafdeling van 40.000 man, of in een labo toevallig de helende kwaliteiten van het bloed van kamelen ontdekten, stuk voor stuk bewijzen ze dat toewijding, vakkennis en innovatie grenzen verleggen in de ultieme strijd van ons allen: die tegen de dood.